BioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

The Company held $52.6 million in cash, cash equivalents and short-term bank deposits as of June 30, 2017. In July 2017, the Company completed a direct placement of its securities for net proceeds of $9.5 million.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.